 Michele Loi
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 5 | 2026 | 285 | 1.240 |
Why?
| | Iatrogenic Disease | 1 | 2026 | 76 | 0.890 |
Why?
| | Teaching Rounds | 1 | 2026 | 73 | 0.860 |
Why?
| | Cross Infection | 1 | 2026 | 262 | 0.770 |
Why?
| | Pleural Effusion | 1 | 2021 | 60 | 0.660 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.610 |
Why?
| | Pharmaceutical Services | 1 | 2020 | 78 | 0.600 |
Why?
| | Renal Insufficiency | 1 | 2021 | 168 | 0.600 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2018 | 29 | 0.560 |
Why?
| | Neutrophil Activation | 1 | 2018 | 85 | 0.550 |
Why?
| | Tranexamic Acid | 1 | 2018 | 53 | 0.540 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 326 | 0.530 |
Why?
| | Quality Improvement | 1 | 2026 | 1289 | 0.500 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2021 | 675 | 0.460 |
Why?
| | Pandemics | 2 | 2023 | 1694 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 384 | 0.440 |
Why?
| | Coronavirus Infections | 1 | 2020 | 378 | 0.440 |
Why?
| | Seizures | 1 | 2018 | 460 | 0.430 |
Why?
| | Antiviral Agents | 1 | 2020 | 767 | 0.420 |
Why?
| | Blood Preservation | 1 | 2018 | 354 | 0.410 |
Why?
| | Erythrocytes | 1 | 2018 | 757 | 0.370 |
Why?
| | Child | 12 | 2026 | 22633 | 0.270 |
Why?
| | Heart Failure | 1 | 2021 | 2323 | 0.270 |
Why?
| | Bed Occupancy | 1 | 2025 | 16 | 0.230 |
Why?
| | Patient Readmission | 2 | 2026 | 758 | 0.190 |
Why?
| | Patient Transfer | 1 | 2026 | 206 | 0.190 |
Why?
| | Infant | 7 | 2026 | 10034 | 0.190 |
Why?
| | Femoral Vein | 1 | 2020 | 38 | 0.160 |
Why?
| | Immunomodulation | 1 | 2020 | 101 | 0.160 |
Why?
| | Child, Preschool | 5 | 2026 | 11787 | 0.150 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2023 | 248 | 0.150 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 293 | 0.150 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 122 | 0.140 |
Why?
| | Blood Buffy Coat | 1 | 2018 | 5 | 0.140 |
Why?
| | Methods | 1 | 2018 | 69 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2023 | 324 | 0.140 |
Why?
| | Filtration | 1 | 2018 | 70 | 0.140 |
Why?
| | Solutions | 1 | 2018 | 166 | 0.140 |
Why?
| | Humans | 16 | 2026 | 144759 | 0.130 |
Why?
| | Chordoma | 1 | 2017 | 17 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 286 | 0.130 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 30 | 0.130 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 56 | 0.120 |
Why?
| | Anticoagulants | 1 | 2020 | 722 | 0.110 |
Why?
| | Immunization, Passive | 2 | 2023 | 87 | 0.090 |
Why?
| | Male | 6 | 2026 | 72315 | 0.090 |
Why?
| | Retinoids | 1 | 2009 | 33 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2026 | 17066 | 0.070 |
Why?
| | Thiazolidinediones | 1 | 2009 | 138 | 0.070 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2009 | 209 | 0.060 |
Why?
| | Inflammation | 1 | 2018 | 2878 | 0.060 |
Why?
| | Critical Illness | 2 | 2023 | 891 | 0.060 |
Why?
| | Female | 4 | 2026 | 78271 | 0.060 |
Why?
| | Streptococcus pyogenes | 1 | 2023 | 41 | 0.050 |
Why?
| | Melanoma | 1 | 2009 | 761 | 0.050 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 80 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2023 | 422 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2023 | 405 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1953 | 0.040 |
Why?
| | Prospective Studies | 2 | 2022 | 7990 | 0.040 |
Why?
| | Acute Disease | 1 | 2020 | 1030 | 0.030 |
Why?
| | Rhabdomyoma | 1 | 2017 | 7 | 0.030 |
Why?
| | Angiomyolipoma | 1 | 2017 | 21 | 0.030 |
Why?
| | Heart Neoplasms | 1 | 2017 | 55 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 770 | 0.030 |
Why?
| | Adolescent | 2 | 2026 | 22428 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4564 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 412 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2925 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5960 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2023 | 6429 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3671 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 2017 | 847 | 0.020 |
Why?
| | Retinoid X Receptors | 1 | 2009 | 38 | 0.020 |
Why?
| | Tetrahydronaphthalenes | 1 | 2009 | 31 | 0.020 |
Why?
| | Benzoates | 1 | 2009 | 50 | 0.020 |
Why?
| | Risk Factors | 1 | 2023 | 10779 | 0.020 |
Why?
| | PPAR gamma | 1 | 2009 | 176 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2022 | 11679 | 0.020 |
Why?
| | Ligands | 1 | 2009 | 673 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2009 | 635 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2009 | 928 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3863 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.010 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 881 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2009 | 2496 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2009 | 3540 | 0.010 |
Why?
| | Adult | 1 | 2023 | 40449 | 0.010 |
Why?
| | Mice | 1 | 2009 | 18339 | 0.010 |
Why?
| | Animals | 1 | 2009 | 38058 | 0.000 |
Why?
|
|
Loi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|